Overexpression of the MDM2 Oncogene in Leukemia and Lymphoma

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53

Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562 · see citing works

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works

Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas

Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,067 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

p53 function and dysfunction

Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

p53: A Frequent Target for Genetic Abnormalities in Lung Cancer

Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M. L., Pass, H. I., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,196 · see citing works

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Gaïdano, G., Ballerini, P. F., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., MAGRATH, I. T., Knowles, D., & Dalla‐Favera, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5413 · Cited by 884 · see citing works

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells

Sarnow, P., Ho, Y.-S., Williams, J., & Levine, A. J. (1982) · Cell · doi:10.1016/0092-8674(82)90356-7 · Cited by 836 · see citing works

Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

Fritsche, M., Haessler, C., & Brandner, G. (1993) · PubMed · Cited by 763 · see citing works

Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · see citing works

Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 562 · see citing works

A comparison of the biological activities of wild‐type and mutant p53

Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 413 · see citing works

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408 · see citing works

Frequent mutation of the p53 gene in human esophageal cancer.

Hollstein, M. C., Metcalf, R. A., Welsh, J. A., Montesano, R., & Harris, C. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.24.9958 · Cited by 383 · see citing works

Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

CAHILLY, L. A., Yang‐Feng, T. L., Francke, U., & George, D. L. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535205 · Cited by 355 · see citing works

MDM2 gene amplification in metastatic osteosarcoma.

Ladanyi, M., Cha, C. H., Lewis, R., Jhanwar, S. C., Huvos, A. G., & Healey, J. H. (1993) · PubMed · Cited by 342 · see citing works

Identification and preliminary characterization of a protein motif related to the zinc finger.

Lovering, R. C., Hanson, I. M., Borden, K. L. B., Martin, S. R., O’Reilly, N., Evan, G. I., Rahman, D., Pappin, D., Trowsdale, J., & Freemont, P. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2112 · Cited by 338 · see citing works

Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.

Juven‐Gershon, T., Barak, Y., Zauberman, A., George, D. L., & Oren, M. (1993) · PubMed · Cited by 332 · see citing works

The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes

Maréchal, V., Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318 · see citing works

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311 · see citing works

The human MDM-2 oncogene is overexpressed in leukemias

Bueso-Ramos, C., Yang, Y. S., deLeon, E., McCown, P., Stass, S. A., & Albitar, M. X. (1993) · Blood · doi:10.1182/blood.v82.9.2617.bloodjournal8292617 · Cited by 294 · see citing works

Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Chen, C. Y., Oliner, J., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271 · see citing works

The mdm-2 gene is induced in response to UV light in a p53-dependent manner.

Perry, M. E., Piette, J., Zawadzki, J., Harvey, D., & Levine, A. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11623 · Cited by 247 · see citing works

Altered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer

LIANES, P., Orlow, I., Zhang, Z., Oliva, M. R., Sarkis, A. S., Reuter, V. E., & Cordon‐Cardo, C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1325 · Cited by 194 · see citing works

Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.

Olson, D. C., Maréchal, V., Momand, J. A., Chen, J., Romocki, C., & Levine, A. J. (1993) · PubMed · Cited by 188 · see citing works

MDM2 Gene Amplification and Transcript Levels in Human Sarcomas: Relationship to TP53 Gene Status

Flørenes, V. A., Mælandsmo, G. M., Forus, A., Andreassen, Å. K., Myklebost, O., & Fodstad, Ø. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1297 · Cited by 188 · see citing works

The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin

Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T., & Saito, H. (1994) · Blood · doi:10.1182/blood.v84.9.3158.3158 · Cited by 170 · see citing works

Mutations of p53 gene and their relation to disease progression in B- cell lymphoma

Ichikawa, A., Hotta, T., Takagi, N., Tsushita, K., Kinoshita, T., Nagai, H., Murakami, Y., Hayashi, K., & Saito, H. (1992) · Blood · doi:10.1182/blood.v79.10.2701.2701 · Cited by 163 · see citing works

Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes.

Zauberman, A., Barak, Y., Ragimov, N., Levy, N., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05941.x · Cited by 151 · see citing works

Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

Landers, J. E., Haines, D. S., STRAUSS, J. F., & George, D. L. (1994) · PubMed · Cited by 143 · see citing works

Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia

Mashal, R. D., Shtalrid, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo, J., Gutterman, J. U., & Deisseroth, A. (1990) · Blood · doi:10.1182/blood.v75.1.180.180 · Cited by 141 · see citing works

The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.

Sheikh, M. S., Shao, Z. M., Hussain, A., & Fontana, J. A. (1993) · PubMed · Cited by 127 · see citing works

Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia

Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123 · see citing works

Mutations of p53 gene and their relation to disease progression in B- cell lymphoma

Ichikawa, A., Hotta, T., Takagi, N., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2701.bloodjournal79102701 · Cited by 123 · see citing works

Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia

Mashal, R. D., Shtalrid, M., Talpaz, M., et al. (1990) · Blood · doi:10.1182/blood.v75.1.180.bloodjournal751180 · Cited by 109 · see citing works

Mutations of the p53 gene in lymphoid leukemia

Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Hirai, H., Ishikawa, F., & Takaku, F. (1991) · Blood · doi:10.1182/blood.v77.6.1153.1153 · Cited by 97 · see citing works

Oncogene Amplification in Urothelial Cancers With p53 Gene Mutation or MDM2 Amplification

Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W., Takahashi, R., Sugiyama, T., & Yoshida, O. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1331 · Cited by 96 · see citing works

The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger

Boddy, M. N., Freemont, P. S., & Borden, K. L. B. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90020-5 · Cited by 91 · see citing works

Over‐expression of the MDM2 gene is found in some cases of haematological malignancies

Quesnel, B., Preudhomme, C., Oscier, D. G., Lepelley, P., Hooghe, M. C., Facon, T. T. F., Zandecki, M., & Fenaux, P. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05044.x · Cited by 64 · see citing works

Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease

Chilosi, M., Doglioni, C., Menestrina, F., Montagna, L., Rigo, A., Lestani, M., Barbareschi, M., Scarpa, A., Mariuzzi, G., & Pizzolo, G. (1994) · Blood · doi:10.1182/blood.v84.12.4295.bloodjournal84124295 · Cited by 45 · see citing works

Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.

Zhang, W., Shay, J. W., & Deisseroth, A. (1993) · PubMed · Cited by 30 · see citing works

p53 and mdm2 are expressed independently during cellular proliferation.

Mosner, J., & Deppert, W. (1994) · PubMed · Cited by 29 · see citing works

Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.

Preudhomme, C., Quesnel, B., Vachée, A., Lepelley, P., Collyn-d'Hooghe, M., Wattel, E., & Fenaux, P. (1993) · PubMed · Cited by 23 · see citing works

Lack of MDM2 amplification in human leukaemia

Ridge, S. A., Dyer, M. J. S., Greaves, M. F., & Wiedemann, L. M. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04754.x · Cited by 21 · see citing works

Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia

Huang, Y. Q., Raphael, B. G., Buchbinder, A., Li, J. J., Zhang, W. G., & Friedman‐Kien, A. E. (1994) · American Journal of Hematology · doi:10.1002/ajh.2830470215 · Cited by 14 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

The MDM2-p53 pathway revisited

Nag, S. A., Jiangjiang, Q., Kalkunte, S. S., Ming-hai, W., & Zhang, R. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414 · see citing works

ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors

Zaika, A., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M. L., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 316 · see citing works

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

Barrans, S., Carter, I. W. J., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A., Morgan, G. J., & Jack, A. (2002) · Blood · doi:10.1182/blood.v99.4.1136 · Cited by 276 · see citing works

Negative regulation of bcl-2 expression by p53 in hematopoietic cells

Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221 · see citing works

p53-Independent Role of MDM2 in TGF-β1 Resistance

Sun, P., Dong, P., Dai, K., Hannon, G. J., & Beach, D. (1998) · Science · doi:10.1126/science.282.5397.2270 · Cited by 194 · see citing works

Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas

Baur, A. S., Shaw, P., Hirt‐Burri, N., Delacrétaz, F., Bosman, F. T., & Chaubert, P. (1999) · Blood · doi:10.1182/blood.v94.5.1773 · Cited by 168 · see citing works

Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression

Beverly, L. J., Felsher, D. W., & Capobianco, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1664 · Cited by 157 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Proteomic analysis of mantle-cell lymphoma by protein microarray

Ghobrial, I. M., McCormick, D., Kaufmann, S. H., Leontovich, A. A., Loegering, D. A., Dai, N. T., Krajnik, K. L., Stenson, M. J., Melhem, M. F., Novak, A. J., et al. (2005) · Blood · doi:10.1182/blood-2004-10-3999 · Cited by 136 · see citing works

Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair

Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413387200 · Cited by 131 · see citing works

Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129 · see citing works

Regulation of the MDM2-p53 Pathway by Ribosomal Protein L11 Involves a Post-ubiquitination Mechanism

Dai, M., Shi, D., Jin, Y., Sun, X., Zhang, Y., Grossman, S. R., & Lu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602596200 · Cited by 122 · see citing works

Mdm2 Promotes Genetic Instability and Transformation Independent of p53

Bouska, A., Lushnikova, T., Plaza, S., & Eischen, C. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01584-07 · Cited by 105 · see citing works

The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant

Anil, B., Riedinger, C., Endicott, J., & Noble, M. E. M. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913004459 · Cited by 95 · see citing works

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96 · see citing works

Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage

Shirangi, T. R., Zaika, A., & Moll, U. M. (2002) · The FASEB Journal · doi:10.1096/fj.01-0617fje · Cited by 96 · see citing works

Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells

Wang, P., Lushnikova, T., Odvody, J., Greiner, T. C., Jones, S. N., & Eischen, C. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210788 · Cited by 86 · see citing works

Balance of Yin and Yang: Ubiquitylation-Mediated Regulation of p53 and c-Myc

Dai, M., Jin, Y., Gallegos, J. R., & Lu, H. (2006) · Neoplasia · doi:10.1593/neo.06334 · Cited by 83 · see citing works

The expression of iASPP in acute leukemias

Zhang, X., Wang, M., Zhou, C., Chen, S., & Wang, J. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.07.001 · Cited by 82 · see citing works

Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B‐cells in chronic lymphocytic leukemia

Quijano, S., López, A., Rasillo, A., Sayagués, J. M., Bárrena, S., Sánchez, M. L., Teodósio, C., Giraldo, P., Giralt, M., Pérez-Caro, M., et al. (2007) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20390 · Cited by 73 · see citing works

Mdm2 affects genome stability independent of p53

Bouska, A., & Eischen, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3732 · Cited by 71 · see citing works

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway

Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69 · see citing works

A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma

Davies, A. J., Lee, A. M., Taylor, C., Clear, A. J., Goff, L. K., Iqbal, S., Heavens, D., Calaminici, M., Norton, A. J., Lister, T. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403802 · Cited by 68 · see citing works

The Many Faces of MDM2 Binding Partners

Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 64 · see citing works

Murine Double Minute-2 Prevents p53-Overactivation-Related Cell Death (Podoptosis) of Podocytes

Thomasová, D., Bruns, H., Kretschmer, V., Ebrahim, M., Romoli, S., Liapis, H., Kotb, A. M., Endlich, N., & Anders, H. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040345 · Cited by 63 · see citing works

Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis

Gramling, M., & Eischen, C. M. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.1 · Cited by 45 · see citing works

Reproducibility of MDM2 and CDK4 Staining in Soft Tissue Tumors

Binh, M. B. N., Sastre‐Garau, X., Guillou, L., Aurias, A., & Coindre, J. (2006) · American Journal of Clinical Pathology · doi:10.1309/vmbp-67qu-nn6q-3j0e · Cited by 44 · see citing works

MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1

Cao, Z., Xue, J., Cheng, Y., Wang, J., Liu, Y., Li, H., Jiang, W., Li, G., Gui, Y., & Zhang, X. (2019) · Oncogene · doi:10.1038/s41388-019-0761-2 · Cited by 38 · see citing works

MdmX regulates transformation and chromosomal stability in p53-deficient cells

Matijasevic, Z., Krzywicka-Racka, A., Sluder, G., & Jones, S. N. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6797 · Cited by 34 · see citing works

Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development

Eischen, C. M., Alt, J. R., & Wang, P. (2004) · Oncogene · doi:10.1038/sj.onc.1208052 · Cited by 32 · see citing works

Direct transcriptional regulation of MDM2 by Fli-1

Truong, A. H. L., Cervi, D. N., Lee, J., & Ben‐David, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1208323 · Cited by 32 · see citing works

MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients

Phang, B. H., Linn, Y. C., Li, H., & Sabapathy, K. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.007 · Cited by 32 · see citing works

B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy

Montserrat, E., Bosch, F., & Rozmán, C. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_1.s93 · Cited by 29 · see citing works

MDM2’s dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities

Gnanasundram, S. V., Malbert-Colas, L., Chen, S., Fusée, L. T. S., Daskalogianni, C., Müller, P., Salomao, N., & Fåhræus, R. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa431 · Cited by 27 · see citing works

Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression

Cressey, R., Pimpa, S., Tontrong, W., Wattananupong, O., & Leartprasertsuke, N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.023 · Cited by 25 · see citing works

p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia

Lahiri, O., Harris, S., Packham, G., & Howell, M. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.07.013 · Cited by 20 · see citing works

Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor–Host Feedback Signaling

Kamer, I., Daniel‐Meshulam, I., Zadok, O., Bab-Dinitz, E., Perry, G., Feniger-Barish, R., Perelman, M., Barshack, I., Ben‐Nun, A., Onn, A., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0395 · Cited by 19 · see citing works

Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma

Riley, M. F., You, M. J., Multani, A. S., & Lozano, G. (2015) · Oncogene · doi:10.1038/onc.2015.88 · Cited by 19 · see citing works

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia

Wang, H., Zhao, D., Nguyen, L. X. T., Wu, H., Li, L., Dong, D. F., Troadec, E., Zhu, Y., Hoang, D. H., Stein, A. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0522-9 · Cited by 19 · see citing works

Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained

Vandenberg, C. J., Waring, P., Strasser, A., & Cory, S. (2014) · Blood · doi:10.1182/blood-2014-04-570770 · Cited by 15 · see citing works

A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.

Lin, J., Jin, X., Page, C., Sondak, V. K., Jiang, G., & Reynolds, R. K. (2000) · PubMed · Cited by 15 · see citing works

Analysis of Nuclear and Cytoplasmic Degradation of p53 in Cells after Stress

Joseph, T. W., & Moll, U. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-408-5:211 · Cited by 13 · see citing works

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 12 · see citing works

Molecular Analysis of Oncogenes, ras Family Genes (N‐ras, K‐ras, H‐ras), myc Family Genes (c‐myc, N‐myc) and mdm2 in Natural Killer Cell Neoplasms

Sugimoto, K., Kawamata, N., Sakajiri, S., & Oshimi, K. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01234.x · Cited by 12 · see citing works

Microbial influences on hormesis, oncogenesis, and therapy: A review of the literature

Clanton, R., Saucier, D., Ford, J. R., & Akabani, G. (2015) · Environmental Research · doi:10.1016/j.envres.2015.06.026 · Cited by 11 · see citing works

Characterization of Novel and Uncharacterized p53 SNPs in the Chinese Population – Intron 2 SNP Co-Segregates with the Common Codon 72 Polymorphism

Phang, B. H., Chua, H. W., Li, H., Linn, Y. C., & Sabapathy, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015320 · Cited by 11 · see citing works

A functional wild-type p53 gene is expressed in human acute myeloid leukemia cell lines.

Sutcliffe, T. L., Fu, L., Abraham, J., Vaziri, H., & Benchimol, S. (1998) · PubMed · doi:10.1182/blood.v92.8.2977.spll5_2977_2979 · Cited by 11 · see citing works

A Functional Wild-Type p53 Gene Is Expressed in Human Acute Myeloid Leukemia Cell Lines

Sutcliffe, T. L., Fu, L., Abraham, J., Vaziri, H., & Benchimol, S. (1998) · Blood · doi:10.1182/blood.v92.8.2977 · Cited by 10 · see citing works

Adoptive Immunotherapy With Antigen‐Specific T Cells

Riddell, S. R., & Greenberg, P. D. (2003) · doi:10.1002/9780470987070.ch29 · Cited by 10 · see citing works

Enhanced Apoptotic Activity of a p53 Variant in Tumors Resistant to Wild-Type p53 Treatment

Atencio, I. A., Avanzini, J. B., Johnson, D. E., Neuteboom, S., Vaillancourt, M.-T., Nielsen, L. L., Hajian, G., Sutjipto, S., Sugarman, B. J., Philopena, J. M., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0416 · Cited by 9 · see citing works

NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas

Reed, S. M., Hagen, J., Muniz, V. P., Rosean, T. R., Borcherding, N. C., Sciegienka, S. J., Goeken, J. A., Naumann, P. W., Zhang, W., Tompkins, V. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112126 · Cited by 8 · see citing works

Combination therapy with the type II anti-CD20 antibody obinutuzumab

Klein, C., Bacac, M., Umaña, P., & Fingerle‐Rowson, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1373087 · Cited by 7 · see citing works

Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance

Herok, M., Wawrzynów, B., Maluszek, M. J., Olszewski, M. B., Żylicz, M., & Żylicz, M. (2021) · Cancers · doi:10.3390/cancers13184501 · Cited by 5 · see citing works

Lymphomes de Burkitt

Ribrag, V., & Bosq, J. (2002) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(02)00044-4 · Cited by 4 · see citing works

Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core

Tripathi, R. S., Anifowose, A., Lu, W., Yang, X., & Wang, B. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2116699 · Cited by 4 · see citing works

Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer

Peirce, S. K. (2010) · Cell Health and Cytoskeleton · doi:10.2147/chc.s4952 · Cited by 3 · see citing works

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Pujals, A., Favre, L., Gaulard, P., & Wiels, J. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s60486 · Cited by 3 · see citing works

Lymphome de Burkitt

Ribrag, V., Camara‐Clayette, V., Bosq, J., & Vasstezky, Y. (2012) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(12)55448-8 · Cited by 3 · see citing works

Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy

Xia, D., Zhu, X., Wang, Y., Gong, P., Su, H.-S., & Xu, X. (2023) · Bioscience Reports · doi:10.1042/bsr20222591 · Cited by 3 · see citing works

The role of p53 in apoptosis

Murphy, M. E., & Levine, A. J. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5287-1_2 · Cited by 3 · see citing works

Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents

Mansour, M. A., Hassan, G. S., Jaballah, M. Y., Serya, R. A. T., Dege, N., Şahın, O., Sharaky, M. M., Zhang, X., Su, R., De, K., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70085 · Cited by 2 · see citing works

Reduced murine double minute 2 and 4 protein, but not messenger RNA , expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia

Salomao, N., Maslah, N., Giulianelli, A., Drevon, L., Aguinaga, L., Gu, X., Cassinat, B., Giraudier, S., Fenaux, P., & Fåhræus, R. (2022) · British Journal of Haematology · doi:10.1111/bjh.18608 · Cited by 2 · see citing works

Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance

Put, N., Włodarska, I., Vandenberghe, P., & Michaux, L. (2012) · InTech eBooks · doi:10.5772/29336 · Cited by 2 · see citing works

Genome-scale functional analysis of the human genes modulating p53 activity by regulating MDM2 expression in a p53-independent manner

Kim, D., Choi, S.-H., Yeom, Y. I., Min, S., & Kim, I. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.063 · Cited by 2 · see citing works

The Intrabody Against Murine Double Minute 2 via a p53-Dependent Pathway Induces Apoptosis of Cancer Cell

Wang, C., Liu, W.-T., Guo, H., Lan, T., Wang, T., & Wang, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115286 · Cited by 1 · see citing works

Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity

Tachibana, S., Otaki, Y., Goto, J., Watanabe, T., & Watanabe, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110252 · Cited by 1 · see citing works

Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science

Zhang, R., & Nag, S. A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_16 · Cited by 1 · see citing works

MDM2 (transformed mouse 3T3 cell double minute 2, p53 binding protein)

Villalona-Calero, M., & Duan, W. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/38406 · Cited by 1 · see citing works

Apoptosis and chemoresistance

Maclean, K. H., & Cleveland, J. L. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.013 · Cited by 1 · see citing works

MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia

Sookaromdee, P., & Wiwanitkit, V. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2019.0179 · Cited by 1 · see citing works

Mouse models in the recognition of tumor antigens

DeLeo, A. B., Beckebaum, S., & Cicinnati, V. R. (2003) · CRC Press eBooks · doi:10.1201/9780203217658.pt1

p53 Tumor Suppressor Opens Gateways for Cancer Therapy

Dai, M., Gallegos, J. R., & Lu, H. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch48

Cytogenetic and genomic assessment of selected lymphoproliferative disorders

Put, N. (2012)

MDM2 (Murine Double Minute 2)

Bang, S., Bhatt, H. C., Chen, Y. Y., & Kurokawa, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101574

MDM2 (Murine Double Minute 2)

Bang, S., Bhatt, H. C., Chen, Y. Y., & Kurokawa, M. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101574-1

Targeting the p53/MDM2 Pathway for Cancer Therapy

Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2

Caractérisation et études précliniques d'un nouvel inhibiteur naturel de MCL-1

Daressy, F. (2020) · doi:10.70675/4e4153f4zba2dz49bcz9862z38251f3f7882

Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies

Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264

Major Cancer Genes

GARTE, S. J. (1998) · Springer eBooks · doi:10.1007/978-1-4615-4989-5_3

The human MDM-2 oncogene is overexpressed in leukemias

Bueso-Ramos, C., Yang, Y. S., deLeon, E., McCown, P., Stass, S. A., & Albitar, M. X. (1993) · Blood · doi:10.1182/blood.v82.9.2617.bloodjournal8292617 · Cited by 294 · see citing works

The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin

Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T., & Saito, H. (1994) · Blood · doi:10.1182/blood.v84.9.3158.3158 · Cited by 170 · see citing works

mdm-2 Oncogene Expression in Non-Hodgkinʼs Lymphomas

Kawamata, N., Miller, C. W., Levy, V., Shintaku, I. P., Koeffler, H. P., & SAID, J. W. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199603000-00006 · Cited by 11 · see citing works

Altered expression of p53 and MDM2 proteins in hematological malignancies.

Koníková, E., & Kusenda, J. (2003) · PubMed · Cited by 24 · see citing works

MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas

Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., Re, V. D., Laurino, L., Carbone, A., & Boiocchi, M. (1995) · Blood · doi:10.1182/blood.v85.11.3239.bloodjournal85113239 · Cited by 35 · see citing works